![雙[三(羥甲基)氨基甲烷],CAS:6976-37-0](http://struc.chem960.com/strucimg/7000/ctzw0nzi34oyob9fnlmhiwee.png)
Detroit R＆D，Inc.成立于1997年，由Hyesook Kim博士創立，致力于提供最高質量的產品，專于研究環境健康科學，高血壓和乳腺癌和前列腺癌領域，包括：生物活性類花生酸，環境雌激素，氧化應激，DNA損傷，非洲爪蟾，藥物代謝，糖基化c-myc和p53，乳腺和前列腺微陣列和傷口愈合。
Detroit R&D公司由Dr. Hyesook Kim創立于1997年，Detroit R&D通過領先的技術提供優質產品，致力于贏得科研工作者的絕對信任。Detroit R&D的特色產品涉及環境健康科學、高血壓、乳腺癌和前列腺癌相關研究領域，包括類花生酸生物活性研究相關產品，如EET,DHET和20-HETE；環境雌激素產品，如BPA，PGHS（也叫COX）；細胞色素P450（CYPs）;谷胱甘肽S-轉移酶(GSTs);氧化應激；DNA損傷；非洲爪蟾蜍；藥物代謝；乳腺和前列腺微陣列；創傷修復等相關產品。
? Research on biologically active eicosanoids such as EET, DHET, 20-HETE ａnd 8-isoprostane, environmental estrogens such as BPA, prostaglandin H synthase (PGHS, also called COX), cytochromes P450 (CYPs), glutathione S-transferases (GSTs), oxidative stress, DNA damage, Xenopus, drug-metabolism, glycosylated c-myc ａnd p53, breast ａnd prostate microarrays ａnd wound healing.
? Novel hypertension (US patents) ａnd breast cancer (patent pending) drug screening kits.
? Anti-breast cancer drug candidates (patent pending).
Detroit R&D has established a track record of success:
· Sales of products to Belgium, Japan, Germany, Australia, Italy, Hong Kong, Thailand, Czech Republic, China, USA, Canada, South Korea, United Kingdom, Brazil, Spain, Kuwait, ａnd Taiwan by direct sales ａnd via distributors.
· We have funding for 17 National Institutes of Health (NIH) SBIR Phase I ａnd II projects (>8.5 million), including hypertension diagnosis, mitochondrial DNA damage ａnd cancer microarray projects.
Pending grants: SBIR Phase II (PI, glycosylated proteins in breast cancer), R21 (PI, prostate cancer cachexia) ａnd Norway Prostate Cancer grant (Co-I, Glycosylated proteins in prostate cancer). > Detroit R&D holds 7 issued ａnd 6 pending patents.
代理商名稱：上海遠慕生物有限公司
供貨：4周左右
Detroit R&D公司由Dr. Hyesook Kim創立于1997年，Detroit R&D通過領先的技術提供優質產品，致力于贏得科研工作者的絕對信任。Detroit R&D的特色產品涉及環境健康科學、高血壓、乳腺癌和前列腺癌相關研究領域，包括類花生酸生物活性研究相關產品，如EET,DHET和20-HETE；環境雌激素產品，如BPA，PGHS（也叫COX）；細胞色素P450（CYPs）;谷胱甘肽S-轉移酶(GSTs);氧化應激；DNA損傷；非洲爪蟾蜍；藥物代謝；乳腺和前列腺微陣列；創傷修復等相關產品。
? Research on biologically active eicosanoids such as EET, DHET, 20-HETE ａnd 8-isoprostane, environmental estrogens such as BPA, prostaglandin H synthase (PGHS, also called COX), cytochromes P450 (CYPs), glutathione S-transferases (GSTs), oxidative stress, DNA damage, Xenopus, drug-metabolism, glycosylated c-myc ａnd p53, breast ａnd prostate microarrays ａnd wound healing.
? Novel hypertension (US patents) ａnd breast cancer (patent pending) drug screening kits.
? Anti-breast cancer drug candidates (patent pending).
Detroit R&D has established a track record of success:
· Sales of products to Belgium, Japan, Germany, Australia, Italy, Hong Kong, Thailand, Czech Republic, China, USA, Canada, South Korea, United Kingdom, Brazil, Spain, Kuwait, ａnd Taiwan by direct sales ａnd via distributors.
· We have funding for 17 National Institutes of Health (NIH) SBIR Phase I ａnd II projects (>8.5 million), including hypertension diagnosis, mitochondrial DNA damage ａnd cancer microarray projects.
Pending grants: SBIR Phase II (PI, glycosylated proteins in breast cancer), R21 (PI, prostate cancer cachexia) ａnd Norway Prostate Cancer grant (Co-I, Glycosylated proteins in prostate cancer). > Detroit R&D holds 7 issued ａnd 6 pending patents.
代理商名稱：上海遠慕生物有限公司
供貨：4周左右
供貨：4周左右
